Moneycontrol

Budget 2023Budget 2023

PARTNERS

  • Tata AIA Life Insurance
  • Hafele
  • Motilal Oswal
Live Now : Nifty Banker 3.0 | India's First Retail Index Traders Online Conference.
Budget 2023
Budget 2023
you are here: HomeNewsTrendsHealth

COVID-19 treatment | Indian drug makers gearing up to make Gilead's remdesivir: Report

Under a licensing agreement, these companies have the right to receive a technology transfer of Gilead's manufacturing process for remdesivir to enable them to scale up production quicker.

May 14, 2020 / 06:37 PM IST

Three Indian drug makers, and a Netherlands-based firm which has a majority of its plants in the country, are gearing up to make antiviral drug remdesivir, according to a report by the Business Standard. Remdesivir is under consideration for treatment of COVID-19 patients.

These companies — Cipla, Hetero Labs, Jubilant LifeSciences and Dutch firm Mylan — have signed licensing pacts with United States-based Gilead.

Follow our LIVE blog for the latest updates of the novel coronavirus pandemic

Under the licensing agreements, the companies have the right to receive a technology transfer of the Gilead manufacturing process for remdesivir to enable them to scale up production more quickly.